Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Decitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 known ✓ | P26358 | 5/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | HBB | P68871 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | PNP | P00491 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decitabine SCHEMBL10030513 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL9999636 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL172264 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL661233 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL1651086 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL4006 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL117721 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL12800474 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20651628 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20769771 | 1.00 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795223-B2 | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia | FORTY SEVEN, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230183814-A1 | PREDICTIVE BIOMARKERS FOR ONVANSERTIB TREATMENT | CARDIFF ONCOLOGY, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230057071-A1 | COMBINATION OF ANTI TIM-3 ANTIBODY MBG453 AND ANTI TGF-BETA ANTIBODY NIS793, WITH OR WITHOUT DECITABINE OR THE ANTI PD-1 ANTIBODY SPARTALIZUMAB, FOR TREATING MYELOFIBROSIS AND MYELODYSPLASTIC SYNDROME | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230058489-A1 | COMBINATION COMPRISING A TIM-3 INHIBITOR AND A HYPOMETHYLATING AGENT FOR USE IN TREATING MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-11583536-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584760-B2 | Dithio ETP derivatives | CITY OF HOPE (US) | 2023-02-21 | — | — | US | disclosed |
| US-11572408-B2 | Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent | VACCINEX, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220401516-A1 | COMBINATION THERAPIES COMPRISING A HYPOMETHYLATION AGENT FOR TREATING CANCER | ALX Oncology Inc. | 2022-12-22 | — | — | US | disclosed |
| US-20220144881-A1 | COMPOUNDS AND METHODS FOR MANUFACTURE OF HYPOMETHYLATING AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| WO-2019014286-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | TEVA CZECH INDUSTRIES S.R.O. (CZ) | 2019-01-17 | — | — | WO | disclosed |
| US-10028973-B2 | Using DNA methyltransferase inhibitors to treat calcific aorta valve disease | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2739154-B1 | VITAMIN B6 DERIVATIVES OF NUCLEOTIDES, ACYCLONUCLEOTIDES AND ACYCLONUCLEOSIDE PHOSPHONATES | MBC PHARMA INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20180155367-A1 | ETP DERIVATIVES | CITY OF HOPE | 2018-06-07 | — | — | US | disclosed |
| US-9982232-B2 | Methods of generating cells with multilineage potential | PIMANDA, John (AU) | 2018-05-29 | — | — | US | disclosed |
| US-20170362572-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170128477-A1 | COMPOSITION FOR INHIBITING MYELOID-DERIVED SUPPRESSOR CELLS COMPRISING DECITABINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AS ACTIVE INGREDIENT | SHAPERON INC. (KR) | 2017-05-11 | — | — | US | disclosed |
| US-20170065639-A1 | MESENCHYMAL STEM CELLS WITH ENHANCED IMMUNOSUPPRESSIVE CAPABILITY | ESCAPE THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170037058-A1 | ETP DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-02-09 | — | — | US | disclosed |
| US-9549988-B2 | Pharmaceutical compounds targeted by MIF affinity-tethered moieties | RJS Biologics (US) | 2017-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057071-A1 | COMBINATION OF ANTI TIM-3 ANTIBODY MBG453 AND ANTI TGF-BETA ANTIBODY NIS793, WITH OR WITHOUT DECITABINE OR THE ANTI PD-1 ANTIBODY SPARTALIZUMAB, FOR TREATING MYELOFIBROSIS AND MYELODYSPLASTIC SYNDROME | CD274, DDIT3, PDCD1 | DNMT1 416/4885ADRB1 1991/4885LMNA 398/4885 |
| US-10028973-B2 | Using DNA methyltransferase inhibitors to treat calcific aorta valve disease | DNMT1, DNMT3A, DNMT3B | DNMT1 1/4885ADRB1 2953/4885LMNA 1885/4885 |
| US-11795223-B2 | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia | CD47, MCL1, MYADM | DNMT1 13/4885ADRB1 4549/4885LMNA 1824/4885 |
| US-20170362572-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | SLC2A3, SLC2A2, SLC2A1 | DNMT1 4610/4885ADRB1 933/4885LMNA 3563/4885 |
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | DNMT1 101/4885ADRB1 3479/4885LMNA 1335/4885 |
| US-11584760-B2 | Dithio ETP derivatives | ETV1, ETV6, DLD | DNMT1 552/4885ADRB1 4459/4885LMNA 3576/4885 |
| US-20170128477-A1 | COMPOSITION FOR INHIBITING MYELOID-DERIVED SUPPRESSOR CELLS COMPRISING DECITABINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AS ACTIVE INGREDIENT | TET2, MYD88, SF3B5 | DNMT1 36/4885ADRB1 4473/4885LMNA 2268/4885 |
| US-20170065639-A1 | MESENCHYMAL STEM CELLS WITH ENHANCED IMMUNOSUPPRESSIVE CAPABILITY | HLA-C, HLA-B, HLA-DRB1 | DNMT1 7/4885ADRB1 2511/4885LMNA 3899/4885 |
| US-11572408-B2 | Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent | HDAC4, DNMT1, HDAC1 | DNMT1 2/4885ADRB1 4285/4885LMNA 3081/4885 |
| US-20220144881-A1 | COMPOUNDS AND METHODS FOR MANUFACTURE OF HYPOMETHYLATING AGENTS | DNMT3A, DNMT1, NSUN2 | DNMT1 2/4885ADRB1 4842/4885LMNA 1765/4885 |
| US-20220401516-A1 | COMBINATION THERAPIES COMPRISING A HYPOMETHYLATION AGENT FOR TREATING CANCER | DNMT1, DNMT3A, MECP2 | DNMT1 1/4885ADRB1 4453/4885LMNA 2700/4885 |
| US-20170037058-A1 | ETP DERIVATIVES | ETV6, ETV1, ELP1 | DNMT1 1806/4885ADRB1 3680/4885LMNA 2291/4885 |
| US-20230058489-A1 | COMBINATION COMPRISING A TIM-3 INHIBITOR AND A HYPOMETHYLATING AGENT FOR USE IN TREATING MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA | MCL1, HAVCR2, BST2 | DNMT1 66/4885ADRB1 4580/4885LMNA 2210/4885 |
| US-11583536-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | DOT1L, CARM1, EZH2 | DNMT1 99/4885ADRB1 3076/4885LMNA 1159/4885 |
| US-20180155367-A1 | ETP DERIVATIVES | ETV6, ETV1, ELP1 | DNMT1 1806/4885ADRB1 3680/4885LMNA 2291/4885 |
| US-20230183814-A1 | PREDICTIVE BIOMARKERS FOR ONVANSERTIB TREATMENT | DDX39B, U2AF1, SF3B5 | DNMT1 123/4885ADRB1 4803/4885LMNA 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.